The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
A Randomized Trial of Sibutramine in the Management of Obese Type 2 Diabetic Patients Treated With Metformin
Abstract
OBJECTIVE—To evaluate the effects of sibutramine (15 and 20 mg/day) on weight, metabolic control, and blood pressure in metformin-treated obese subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS—A 12-month randomized prospective placebo-controlled double-blind study was performed. It included 21 primary and secondary care centers in England, Canada, France, and Belgium. A total of 195 subjects (44% male) with type 2 diabetes and a BMI >27 kg/m2 were studied. Changes were assessed in weight, blood pressure and resting heart rate, HbA1c, fasting glucose, and lipids. RESULTS—Sibutramine induced significant weight loss (P < 0.001) with both 15 mg/day (5.5 ± 0.6 kg at 12 months) and 20 mg/day (8.0 ± 0.9 kg), whereas placebo did not (0.2 ± 0.5 kg). Weight loss ≥10% was achieved by 14 and 27% of subjects receiving 15 and 20 mg, respectively, but by none given placebo. Glycemic control improved in parallel with weight loss, and subjects who lost ≥10% weight showed significant decreases in both HbA1c (1.2 ± 0.4%, P < 0.0001) and fasting plasma glucose (1.8 mmol/l, P < 0.001). HDL cholesterol increased slightly with the higher dose, whereas plasma triglycerides fell with both doses, especially in subjects with weight loss of ≥10% (a 29% decrease, P < 0.01). Treatment was generally well tolerated. Sibutramine treatment raised sitting diastolic blood pressure by ≥5 mmHg in a higher proportion of patients than did placebo (43% with 15 mg/day vs. 25% with placebo, P < 0.05), but this effect was less evident in subjects who had a weight loss of ≥10% weight. Pulse rate increased significantly more with sibutramine, being ≥10 bpm higher in 42% of treated patients versus 17% with placebo (P < 0.01). CONCLUSIONS—Sibutramine can be an effective adjunct to metformin treatment in selected obese type 2 diabetic subjects and improves metabolic control in individuals who lose weight.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
Effect of sibutramine on weight maintenance after weight loss: a randomised trial
James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M., & Gaal, L. F. V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03491-7 · Cited by 817
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Obesity, weight loss and prognosis in type 2 diabetes
Lean, M. E. J., Powrie, J. K., Anderson, A. S., & Garthwaite, P. H. (1990) · Diabetic Medicine · doi:10.1111/j.1464-5491.1990.tb01375.x · Cited by 318
Fujioka, K., Seaton, T. B., Rowe, E., Jelinek, C. A., Raskin, P., Lebovitz, H. E., Weinstein, S. P., & Group, T. S. C. S. (2000) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00081.x · Cited by 244 · cited 2×
“Sibutramine is generally well tolerated, although some patients show evidence of increased sympathetic cardiovascular tone, with mild tachycardia and rises in blood pressure (12,13).”
Cited by
Franz, M. J., VanWormer, J. J., Crain, A. L., Boucher, J. L., Histon, T., Caplan, W., Bowman, J. D., & Pronk, N. P. (2007) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2007.07.017 · Cited by 1,559
Lau, D. C. W., Douketis, J. D., Morrison, K. M., Hramiak, I. M., Sharma, A. M., Ur, E., & Panel, F. M. O. T. O. C. C. P. G. E. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.061409 · Cited by 1,154
Self-citationVillareal, D. T., Apovian, C. M., Kushner, R. F., & Klein, S. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.5.923 · Cited by 880
Meta-Analysis: Pharmacologic Treatment of Obesity
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L. R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P. G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00012 · Cited by 774
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753
Metadata
- Authors
- McNulty, S. J., Ur, E., Williams, G., & For the Multicenter Sibutramine Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2003-01-01
- Volume
- 26
- Issue
- 1
- Pages
- 125-131
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2106623465
- Cited by
- 166
- References
- 8
- FWCI
- 12.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Trial of Sibutramine in the Management of Obese Type 2 Diabetic Patients Treated With Metformin. https://app.cochat.ai/papers/10.2337/diacare.26.1.125
- The paper
- McNulty, S. J., Ur, E., Williams, G., & For the Multicenter Sibutramine Study Group. (2003). A Randomized Trial of Sibutramine in the Management of Obese Type 2 Diabetic Patients Treated With Metformin. Diabetes Care. https://doi.org/10.2337/diacare.26.1.125
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.